GENSCRIPT BIO (01548) surged 6.61% during Monday's intraday trading session, extending its recent rally as positive news flow from its associate company and the broader sector fueled investor optimism.

The move came after the company's associate, Legend Biotech, reported robust second-quarter net trade sales for its CARVYKTI therapy of approximately $657 million, marking a 49.4% year-over-year increase and 10% sequential growth. First-half sales reached $1.254 billion, up 55.1% year-over-year. Additionally, GENSCRIPT BIO is set to hold a board meeting on August 15 to review and approve its interim results for the six months ended June 30, with the potential for an interim dividend adding to market enthusiasm.

The broader CXO sector also provided a tailwind, with peers like WuXi AppTec reporting strong adjusted net profit growth of about 89% year-over-year for the first half, lifting overall industry sentiment. These multiple catalysts combined to drive the stock's sharp intraday advance.